Management of NTD thalassemia

Jump to section

Monitoring

Unmet Need

Frequent monitoring and management of NTD patients with thalassemia is critical to identify and help mitigate the development of morbidities^1,2

Pulmonary hypertension

Iron overload

Hypercoagulability

Thrombotic disease

Liver disease

Endocrine and bone disease

Leg ulcers

Extramedullary hematopoiesis

Patients with thalassemia should receive a long-term thalassemia management plan for optimal care³

Stay up to date with the latest
thalassemia management guidelines

Get the TIF Guidelines for NTD Beta-Thalassaemia

Get the TIF Guidelines for Alpha-Thalassaemia

Get the Guidelines for the Management of Transfusion Therapy for Thalassemia

Thalassemia treatment options are needed that target the underlying pathophysiology of thalassemia³

There are currently limited treatment options that specifically target ineffective erythropoiesis and hemolysis in NTD patients with alpha- or beta-thalassemia.

Connect your patients with a Clinical Nurse Educator (CNE), who works closely with patients, families, and their care teams to offer individualized support,* educational resources, and community connections.

Connect with a CNE here

*A Clinical Nurse Educator does not provide medical advice.

For Healthcare Professionals

Stay up to date

Get the latest thalassemia information.

Required field*

First Name*

Last Name*

Email Address*

Your National Provider Identifier (NPI) number*Look up your NPI number

Specialty

Practice Setting

I'd like to schedule a meeting with an Agios representative

By clicking “SUBMIT”, I consent that the information I am providing may be used by Agios and its agents to keep me informed about disease state education, products, or other opportunities that may be of interest to me via e-mail. I understand and agree that the information I provide will be used in accordance with the Agios Privacy Policy, including to provide me with marketing information, offers, and promotions, and to contact me for my opinions regarding Agios products, programs, and services.*

References:

1. Musallam KM, Cappellini MD, Coates TD, et al. Alpha-thalassemia: a practical overview. Blood Rev. 2024;64:101165. doi:10.1016/j.blre.2023.101165 2. Taher AT, Musallam KM, Cappellini MD. ß-Thalassemias. N Engl J Med. 2021; 25(8):727-743. doi:10.1056/NEJMra2021838 3. Taher AT, Musallam KM, Cappellini MD. Guidelines for the Management of Non-Transfusion-Dependent β-Thalassemia. 3rd ed. Nicosia, Cyprus: Thalassemia International Federation; 2023.